**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 23204**

**Manuscript Type: Review**

**Genetic variation of occult hepatitis B virus infection**

Zhu HL *et al.* HBV variation of occult infection

Hui-Lan Zhu, Xu Li, Jun Li, Zhen-Hua Zhang

**Hui-Lan Zhu, Xu Li, Zhen-Hua Zhang,** Department of Infectious Diseases, the First Affiliated Hospital, Anhui Medical University, Hefei 230022, Anhui Province, China

**Jun Li, Zhen-Hua Zhang,** School of Pharmacy, Anhui Medical University, Hefei 230032, Anhui Province, China

**Author contributions:** Zhu HL contributed to analysis and interpretation of data, drafting the article; Li X and Li J contributed to revising the article for important intellectual content; Zhang ZH contributed to conception and design, analysis and interpretation of data, drafting and revising the article for important intellectual content.

**Supported by** the Specialized Research Fund for the Doctoral Program of Higher Education of China, No. 20093420120005; and the National Science Foundation of China, No. 81273142.

**Conflict-of-interest statement:** The authors have declared that no potential conflict of interest exists.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon

this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**Correspondence to: Zhen-hua Zhang, MD, PhD,** Department of Infectious Diseases,The First Affiliated Hospital,Anhui Medical University,218 Jixi Road, Hefei 230022, Anhui Province, China. zzh1974cn@163.com

**Telephone:** +86-551-62922912

**Fax:** +86-551-62922912

**Received:** October 29, 2015

**Peer-review started:** October 30, 2015

**First decision:** November 27, 2015

**Revised:** December 13, 2015

**Accepted:** December 30, 2015

**Article in press:**

**Published online:**

**Abstract**

Occult hepatitis B virus infection (OBI), characterized as the persistence of hepatitis B virus (HBV) surface antigen (HBsAg) seronegativity and low viral load in blood or liver, is a special form of HBV infection. OBI may relate mainly to mutations in the HBV genome, although the underlying mechanism of it remains to be clarified. Mutations especially within the immunodominant “α” determinant of S protein are “hot spots” which could attribute to the occurrence of OBI via affecting antigenicity and immunogenicity of HBsAg or replication and secretion of virion. Clinical reports accounted for a large proportion of previous studies on OBI, while functional analyses especially those based on full-length HBV genome were rare.

**Key words:** Hepatitis B virus; Occult; Variation; Hepatitis B surface antigen

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** With the error-prone reverse transcription during replication, hepatitis B virus (HBV) displays a high rate of mutation and a single mutation may affect the biological properties of HBV. Occult HBV infection (OBI) is a special form of HBV infection and a frequent phenomenon. Many previous publications have explored the association of OBI with the “hot spots” mutations which occur within the immunodominant “α” determinant of S proteins. However, there is no review available to elaborate the relationship between OBI and mutations throughout the entire HBV genome. This review attempts to provide a comprehensive summary of HBV genetic variants that have been suggested to be associated with OBI.

Zhu HL, Li X, Li J, Zhang ZH. Genetic variation of occult hepatitis B virus infection. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

hepatitis B virus (HBV), classified as a DNA viruses, replicates via reverse transcription which is itself error-prone to generate an RNA intermediate, thus the mutation rate of HBV is intermediate between those of RNA viruses and conventional DNA viruses[[1](#_ENREF_1)]. The nucleotide mutation rate of HBV is estimated to be 10-5-10-6 per site per year, about 10 fold higher than that of other DNA viruses, and might increase 100 fold after liver transplantation[[2](#_ENREF_2),[3](#_ENREF_3)]. Mutations are commonly encountered especially in the basal core promoter (BCP), the pre-core region (Pre-C), the polymerase (P) gene and the “α” determinant of S protein, and single or multiple mutations occurred may affect biological properties of HBV[[4](#_ENREF_4)]. As a special form of HBV infection and a frequent phenomenon, occult HBV infection (OBI) was firstly reported in 1978 and has been studied further since then[[5](#_ENREF_5)]. In 2008, the Taormina expert meeting defines OBI as presence of HBV DNA in the liver of individuals negative for HBV surface antigen (HBsAg) testing, and the amount of HBV DNA in the serum is usually lower than 200 IU/ml or undetectable[[6](#_ENREF_6)]. OBI is characterized by the persistence of low level viremia and HBsAg seronegativity and can be grouped into seropositive (anti-HBc and/or anti-HBs positive) and seronegative (anti-HBc and anti-HBs negative)[[7](#_ENREF_7)]. OBI harbors the potential risk of HBV transmission through blood transfusion, organ transplantation, and hemodialysis as well as from occult infected or HBsAg-positive mothers to newborns[[8](#_ENREF_8),[9](#_ENREF_9)]. Although the clinical and biochemical symptoms of most OBIs are not severe, there is still a risk of developing serious liver diseases such as liver cirrhosis (LC) and hepatocellular carcinoma (HCC)[[10](#_ENREF_10)]. In fact, meta-analysis and other findings have revealed that OBI remains the pro-oncogenic properties of HBV and serves as a risk factor for the development of HCC[[11-13](#_ENREF_11)]. Suppression of viral replication is reversible in the case of OBI, and reactivation of OBI and/or development of fulminant hepatitis failure (FHF) has been reported in patients following chemotherapy or immunosuppressive therapy, after transplantation as well as co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)[[14-16](#_ENREF_14)].

**PREVALENCE OF OBI**

OBI is a health problem worldwide and its prevalence is affected by several factors such as the prevalence of HBV infection, the study population and the sensitivity of diagnostic assays[[17](#_ENREF_17),[18](#_ENREF_18)]. OBI is significantly associated with the endemicity of HBV infection but not restricted to countries highly endemic for HBV[[10](#_ENREF_10),[17](#_ENREF_17),[18](#_ENREF_18)]. The prevalence of OBI in blood donors from China, South Korea and Japan was reported to be 0.11%-0.13%, 0.016% and 1.01%, respectively[[19-22](#_ENREF_19)]. The incidence of OBI in anti-HBc positive donors was reported from 0% to 15%[[23](#_ENREF_23),[24](#_ENREF_24)]. The detection rate of OBI in HIV infection was reported from 0% to 89%[[25](#_ENREF_25),[26](#_ENREF_26)]. In the context of chronic HCV infection, the percentage of OBI was reported ranging from 0% to 52%[[27](#_ENREF_27),[28](#_ENREF_28)]. Previous studies conducted in hemodialysis patients indicated a prevalence of OBI from 0% to 36%[[29](#_ENREF_29),[30](#_ENREF_30)]. OBI was detected in 32% of patients with cryptogenic liver cirrhosis in Hong Kong, an area with high prevalence of HBV infection[[31](#_ENREF_31)]. The prevalence of OBI was reported to be 70.4% among HBsAg-negative HCC patients in China[[32](#_ENREF_32)].

The identification of OBI largely depends on the testings for HBsAg and HBV DNA. There are several commercial HBsAg assays with different sensitivities and specificities, which mainly depend on the use of anti-HBs antibodies varying in terms of sensitivity and specificity. Some diagnostic HBsAg assays are based on monoclonal antibodies and recognize limited types of HBsAg variants. In comparison, assays that utilize polyclonal antibodies show higher sensitivity and specificity for the detection of various types of HBsAg mutants[[33](#_ENREF_33),[34](#_ENREF_34)]. Due to the low viremia of OBI, small amount of HBsAg below the detection limit of tests could not be reliably recognized. Highly sensitive real-time quantitative polymerase chain reaction (PCR) is strongly recommended for HBV nucleic acid testing (NAT) for its capability to uncover low level of HBV DNA in serum but also harbor a risk of false-positive results[[35](#_ENREF_35),[36](#_ENREF_36)]. Anti-HBc screening can reduce the risk of HBV transmission but may possibly provide false-positive results. It is worth noting that, the nature of specimen tested (blood sample or liver tissue), the amount of specimen as well as contamination risks can also affect the detection of OBI.

Many studies have been conducted on OBI prevalence. However, cautions must be taken when results from different studies are compared, since differences in groups of people studied, areas selected as well as diagnostic assays used can significantly affect the results.

**MECHANISM OF OBI**

The mechanism of OBI is complicated and remains to be clarified. Both host and viral factors contribute to the occurrence of OBI. For example, the persistence of covalently closed circular DNA (cccDNA) in hepatocytes, suppression and detection failure of virion replication as well as proteins secretion are involved[[37](#_ENREF_37),[38](#_ENREF_38)]. In addition, methylation of the HBV genome, microRNAs (miRNAs) and histone modification have been reported to affect the regulation of HBV replication and expression through epigenetic mechanisms, increasing the possibility that epigenetic regulation may also be associated with OBI[[39](#_ENREF_39)].

***Viral factors***

Genetic mutations may contribute to OBI. Mutations have an impact on the expression, secretion and antigenicity of HBsAg and cause failure in detecting HBsAg by commercial diagnostic tests. HBV is prone to mutations and exists as quasispecies to facilitatie viral survival. Point mutations and insertion as well as deletion mutations are commonly encountered in OBI, and mutations in all open reading frames (ORFs) of HBV could directly or indirectly affect detection of HBsAg while most studies are focused on mutations in Pre-S/S gene. Besides, mutations are associated with the suppression of viral replication typical of OBI, which in turn affects HBsAg expression and secretion[[40](#_ENREF_40)]. Circulating immune complexes consisting of HBsAg and anti-HBs may be associated with Pre-S/S gene mutations and impair the binding efficiency of HBsAg capture antibodies to HBsAg in serum, leading to immune escape[[41](#_ENREF_41),[42](#_ENREF_42)].

Low level of HBV replication may be correlated with OBI. Compared to HBsAg-positive infection, OBI always has lower (< 200 IU/ml) or even undetectable HBV DNA in serum[[18](#_ENREF_18)]. Although HBV DNA from the liver is more reliable than circulating HBV DNA for recognition of OBI, the levels of intra-hepatic HBV DNA and cccDNA in OBI were also found to be lower than those in HBsAg-positive infection[[38](#_ENREF_38),[43](#_ENREF_43)]. Thus, the low level of HBV replication may be related to OBI.

HBV genome methylation is related to the development of OBI. Hypermethylation of HBV has been observed in isolates from OBI patients, and HBV CpG islands 1 and 2 were more frequently methylated in HBsAg positive infections and OBIs, respectively[[44](#_ENREF_44),[45](#_ENREF_45)].

***Host factors***

The alternation of host immunologic responses is associated with OBI. In patients with spontaneous and therapy-induced HBsAg clearance, residual HBV may present in serum, liver and lymphatic system for a long time[[46](#_ENREF_46),[47](#_ENREF_47)]. Similarly, using a woodchuck models, the closet natural model of HBV infection, Michalak *et al*[[48](#_ENREF_48),[49](#_ENREF_49)] described the low-level but life-long persistence of woodchuck hepatitis B virus (WHV) DNA and cccDNA in both liver and lymphatic system in animals recovered from acute WHV invasion. Based on these data, they suggested that the hard-to-eliminate cccDNA made the complete clearance of WBV difficult to accomplish and might contribute to WBV reactivation, and further speculated that HBV cccDNA may act similarly to WBV cccDNA. Therefore, latency of HBV in liver and in extra-hepatic tissues and cells provide favorable condition for the occurrence of OBI[[50](#_ENREF_50)]. Reactivations of overt HBV infections and OBIs have been frequently described in HBV infected patients with suppressed immune system, suggesting that HBV was inhibited rather than being cleared in the setting of immunosuppression. Colson *et al*[[51](#_ENREF_51)] investigated 16 anti-HBc positive patients who developed HBV reactivation following chemotherapy and demonstrated that an increased variability within HBsAg and HBV reverse transcriptase (RT) were detected in these patients. OBI has also been reported in vaccinated children from Taiwan and Iran[[52](#_ENREF_52),[53](#_ENREF_53)]. It is speculated that the patients’ immune response to HBV infection may be related to OBI by greatly controlling HBV activity, putting pressure on secretion of HBsAg and other HBV-secreted proteins as well as promoting the screening of mutants.

In addition to altered host immunologic responses, host genetic factors are also linked to OBI. Related studies are focused on human leukocyte antigen (HLA) which plays an important role in modulation of immune responses, and HLA polymorphisms are considered as vital factors in determining HBV infections outcome (persistence or clearance)[[54](#_ENREF_54)]. Previous studies showed that HLA-A2 expression was correlated with protection against HBV infection, while significantly decreased intensity of HLA-A2 expression on peripheral blood mononuclear cells (PBMCs) was detected in some OBI patients compared to healthy controls and may contribute to HBV resistance[[55](#_ENREF_55)]. Serum level of IL-10 was markedly higher in some OBI patients than that in healthy controls, and polymorphisms of IL-10 promoter were found with significant differences between OBIs and healthy controls, implying a relationship between IL-10 and OBI[[56](#_ENREF_56),[57](#_ENREF_57)].

Host epigenetic modification may be related to OBI. miRNAs of host cells could regulate expression of some host genes and exert effect on HBV replication and expression[[58](#_ENREF_58)]. A profile of HBV-specific serum miRNAs has been reported with a high accuracy to separate OBI cases from healthy controls (sensitivity: 99.9%, specificity: 99.8%), raising the possibility that it may serve as effective biomarkers in OBI detection[[59](#_ENREF_59)]. Epigenetic modifications of cccDNA-bound histones may regulate HBV replication and transcription, acetylation and methylation are the most common kinds of histone modification. Previous studies showed that HBV replication could be regulated by the acetylation status of cccDNA-bound H3 and H4 histones in CHB patients and this regulation has been confirmed by transfection experiments[[60](#_ENREF_60)].

***Other factors***

Other factors may be connected with OBI, such as interference by other viruses. Concomitant presence of chronic HCV infection exerts negative effect on HBV. HBV DNA levels increased during Interferon-Ribavirin therapy of HCV but decreased after a viral breakthrough of HCV[[61](#_ENREF_61),[62](#_ENREF_62)]. Moreover, *in vitro* studies also demonstrated the inhibitory effect exerted by HCV core protein on HBV replication and expression[[63](#_ENREF_63)].

**PRE-S/S MUTATIONS**

***Pre-S/S point mutation***

Pre-S/S gene encodes three envelope proteins named large (L), middle (M) and small (S) protein, and S protein corresponds to HBsAg[[64](#_ENREF_64)]. Pre-S/S has a relatively high mutation rate among all ORF(s), and mutations of Pre-S/S gene have been studied extensively. Point mutations occurr of Pre-S/S gene may affect HBsAg in two different aspects, (1) mutations may affect antigenicity, immunogenicity, secretion and/or expression of HBsAg, and lead to detection failure of HBsAg[[33](#_ENREF_33),[65](#_ENREF_65)]; (2) mutations may reduce or even abolish the replication and/or secretion of virion and exert negative effect on HBsAg[[66](#_ENREF_66),[67](#_ENREF_67)]. Amino acid (aa) substitutions of HBsAg are mostly frequently clustered in the “α” determinant which is located at aa124-147 of S protein. The “α” determinant is rich in cysteine and two loops are formed by disulfide bonds between C124 and C137 as well as C139 and C147 to maintain the conformational structure and antigenicity of HBsAg. The “α” determinant is a relatively conserved region within major hydrophilic region (MHR) between aa100 to aa169, which serves as the most important antigenic determinant in all HBV strains and is essential to the detection of HBsAg and development of HBV vaccines[[64](#_ENREF_64),[68](#_ENREF_68)]. Amino acids within the region between 120 to 123 were proven to be crucial for the antigenicity of HBsAg[[69](#_ENREF_69)]. Therefore, single or multiple point mutations occurred within or adjacent to the “α” determinant may change the antigenicity and conformation of HBsAg, resulting in failure to detect HBsAg. Various point mutations of HBsAg have been observed in OBIs (Figure 1).

The amino acid mutations were mostly detected in the MHR in OBIs, and many previous reports documented that the mutation rate in the MHR especially in the “α” determinant was higher in OBIs compared to that of HBsAg-positive patients[[66](#_ENREF_66),[70](#_ENREF_70)]. A number of Pre-S/S mutations were observed in both OBIs and HBsAg-positive patients (Figure 1), while it is speculated that they may not be associated with OBI. Clinically observed Pre-S/S mutations in OBIs summarized in Figure 1 indicate that: (1) Some mutations occurred in both OBIs and HBsAg-positive patients, while some mutations were only detected in OBIs; (2) Some mutations were found outside the “α” determinant and were located at the N-terminus or C-terminus of MHR or outside MHR; (3) Some mutations also corresponded to the amino acid substitutions in P region; (4) Some amino acid substitutions were specific for genotypes, subgenotypes or subtypes, while the clinical significance of them in OBIs remains to be determined; (5) Point mutations in the first loop of “α” epitope (aa124-137) occurred more frequently in OBI isolates from unvaccinated person[[71](#_ENREF_71)], while point mutations in the second loop of “α” epitope (aa138-147) were more frequently isolated from OBI patients after immune prophylaxis[[72](#_ENREF_72)]; and (6) Apart from point substitutions, there were other types of mutations or combined mutations. However, further *in vivo* and *in vitro* studies are required to explore the effects of point mutations on the occurrence of OBI.

In order to elucidate the role of mutations in the occurrence of OBI, plasmids of Pre-S/S variants isolated from the sera and liver tissues of OBI patients were constructed by site-directed mutagenesis and transfected into cell lines or introduced into animal models. The antigenicity, immunogenicity and secretion of HBsAg as well as the replication and secretion of virion were then analyzed. This strategy has been extensively applied to point mutations in Pre-S/S gene (Table 1 and Figure 2). Similarly, these functional analyses also fit to research on other HBV-related mutations[[73](#_ENREF_73)]. To date most *in vivo* and *in vitro* studies have been limited to Pre-S/S gene, only a few functional studies were performed with full-length, replication-competent HBV genomes, and it’s hard to know whether some point mutations interfere with the replication of virion and secretion of antigens and play a role in the occurrence of OBI[[40](#_ENREF_40),[74](#_ENREF_74)].

Documented by many studies, substitutions of wild-type cysteines and G145R in the “α” determinant cause conformational and phenotypic changes in HBsAg (Table 1 and Figure 2)[[33](#_ENREF_33),[66](#_ENREF_66),[71](#_ENREF_71),[78](#_ENREF_78)]. El Chaar *et al*[[80](#_ENREF_80)] restored the cysteines at positions 124 and 137 in recombinant surface protein (rS protein) from OBIs and expressed them in yeast, improved antigenic reactivity of HBsAg were observed. However, restoration of cysteine at position 147 and G145R didn’t improve the impaired reactivity of HBsAg. Y100C was commonly found in OBIs, but transfection experiments revealed that Y100C plasmid resulted in higher extracellular HBsAg levels than the wild-type plasmid, implying the mutation alone could not explain the decrease of HBsAg secretion and/or affinity to antibodies[[76](#_ENREF_76)]. *In vitro* studies have found that some point mutations could strongly influence the secretion of HBsAg and that these mutations may interfere with the secretion of HBsAg in some cases, leading to the failure of HBsAg detection[[86](#_ENREF_86)]. Some point mutations were found to affect HBV replication in hepatoma cell lines and/or in mice and vesicular transport of infectious virion of HBV (*i.e.*, Dane particles) from the cell[[66](#_ENREF_66)].

Glycosylation with the most common kind being N-linked glycosylation is required for crucial biological functions of many enveloped viruses, since it can impart various advantages to virus survival and virulence[[88](#_ENREF_88)]. Point mutations can affect biogenesis, stability and antigenicity of HBV through modification of the envelope protein glycosylation pattern[[89](#_ENREF_89),[90](#_ENREF_90)]. The envelope protein of HBV possesses an N-glycosylation site at N146 of the “α” determinant, and the removal of this site decreased the production of virion without affecting the synthesis and stability of HBsAg (Table 1 and Figure 2)[[78-80](#_ENREF_78)]. Several positions in the envelope proteins can substitute for position 146 as the potential glycosylation site[[78](#_ENREF_78)]. Previous studies reported that T123N and K160N were each capable to create new glycosylation sites and caused a decrease of HBsAg antigenicity. These two point substitutions were found to mainly affect the virion assembly and secretion without interfering with the virion replication. K122I and A159G appeared to affect biological properties of HBsAg and facilitated glycosylation of HBV. A159G was proven to greatly impair the assembly and secretion of virion, but K160N and A159G/K160N slightly reduced the virion production, thus K160N could partially rescue the negative effect exerted by A159G on secretion of virion[[82](#_ENREF_82)]. M133T mutation could create additional glycosylation site131NST133 and partially rescued the impaired secretion of virion induced by some point mutations such as I110M, G119E, G145R, N146Q/S and R169H, while preventing glycosylation could destroy the effect of the M133T mutation[[78](#_ENREF_78),[79](#_ENREF_79),[82](#_ENREF_82)]. M133T alone is not able to generate a glycosylation site, unless there is a N at aa131 as in the reference sequences of HBV genotype A, the T131N/M133T double mutations were frequently observed in OBIs infected with non-A genotypes, and change of T131N could also abrogate the secretion-rescue effect exerted by M133T[[78](#_ENREF_78),[79](#_ENREF_79)].

Among OBI related mutations, some point mutations cause HBsAg secretion deficiency by affecting the start codons of Pre-S/S gene or causing in amino acid substitutions[[91](#_ENREF_91)]. A purine at the -3 position (*i.e.*, 3-nt upstream from the translational start site) of AUG initiator codon is essential for protein expression, and substituted by a pyrimidine at this site makes translation more sensitive to changes at positions -1, -2 and +4 (*i.e.*, 4-nt downstream from the translational start site)[[92](#_ENREF_92)]. Point mutations around the initiator codons of HBV S gene (*i.e.*, nt155-157) such as A152T and A152G/G158C double mutations reduced HBsAg secretion by 70% and 30%, respectively, but maintained efficient virion secretion, while A152T combined with C154A or G158A completely abolished HBsAg secretion[[91](#_ENREF_91)]. Some point mutations have an effect on RNA slicing. Hass *et al*[[93](#_ENREF_93)] found that ntG458A inactivated 5’ splice site of the Pre-S2/S mRNA and reduced the level of Pre-S2/S mRNA as well as HBsAg expression and caused a low-replication phenotype. Among some genotype D OBIs, ntG173T was able to activate *in cis* a previously inactive splice acceptor site at neighboring nt202 and promote RNA splicing from nt2986 to 202. The novel splicing could abolish the L, M and S proteins without affecting the functions of polymerase[[94](#_ENREF_94)].

***Pre-S/S deletion***

Deletion mutations in Pre-S/S have been frequently reported in OBI and deletions covering the Pre-S/S promoters may affect RNA splicing and exert an effect on expression of one or more envelope proteins (Figure 3)[[50](#_ENREF_50),[74](#_ENREF_74)]. In cases of OBI, in-frame 183-bp deletions (nt3019-3201 or nt2983-3167) were commonly detected in Pre-S1 region. Functional analyses found that variants harboring the 183-bp deletion mutation didn’t express HBsAg or secret viral particles when transfected in cell lines, although they appeared to be replication-competent[[50](#_ENREF_50),[95-97](#_ENREF_95)]. A CCAAT element (nt3143-3147) and binding sites for SP1 transcription factor are located in the Pre-S2/S promoter (nt2960-3180), which are completely and partially overlapped by the 183-bp deletion mutation, respectively[[98](#_ENREF_98),[99](#_ENREF_99)]. The CCAAT element is where cellular transcription factor NF-Y binds to and plays a key role in activating S promoter and regulating the ratio of Pre-S and S mRNA. Mutations in the CCAAT element down-regulate the level of Pre-S1 mRNA while up-regulate that of Pre-S2/S mRNA, resulting in decreased amount of L protein but increased amounts of M and S proteins[[100](#_ENREF_100)]. The SP1 sites also regulate S promoter activity and production of Pre-S and S mRNA but exert a weaker effect than the CCAAT element. Mutations occur at SP1 sites affect the ratio of Pre-S/S mRNA as well as expression of envelope proteins[[98](#_ENREF_98),[99](#_ENREF_99)]. The specific ratio of L protein and S protein is essential for assembly of the envelope particles, since an excessively high or low L/S proteins ratio could alter HBsAg assembly and secretion and reduce virion secretion[[91](#_ENREF_91),[101](#_ENREF_101),[102](#_ENREF_102)]. Similarly, Xu and Yen reported a 129-bp deletion within the Pre-S2/S promoter, which affected Pre-S2/S mRNA production leading to complete abolishment of HBsAg secretion[[103](#_ENREF_103)]. Chaudhuri *et al*[[74](#_ENREF_74)] described several fragment deletions containing Pre-S2/S promoter in OBIs and demonstrated that full-length HBV genomes harboring these deletion variants could drastically decrease the expression of HBsAg by transfected HepG2 cells. Besides, Pre-S1 region possesses hepatocyte-binding site (aa21-47), which is vital to virion assembly and transport from the hepatocyte, and deletions covering this site may affect virion binding to and being secreted out of the hepatocyte[[104](#_ENREF_104)].

In OBIs, deletions in Pre-S2 region were frequently detected at aa8-23, which are also associated with progression of liver diseases[[74](#_ENREF_74),[105](#_ENREF_105)]. These deletions overlap with the binding site for cross-linked human serum albumin (aa17-28) in the Pre-S2 region, which is involved in the attachment of HBV to the human hepatocyte membrane and mutations affecting this site may decrease the infectivity of HBV[[106](#_ENREF_106)]. Deletions in Pre-S2 region may influence expression of M protein, while which is dispensable for formation and secretion of virion *in vivo* and *in vitro*[[91](#_ENREF_91),[107](#_ENREF_107)]. Deletions in the Pre-S2 region may be related to OBI by affecting the production of L protein. Deletions in the Pre-S2 region shorten the gap between the Pre-S2/S promoter and the start codon of S mRNA, in turn leading to an overproduction of L protein and an alternation of L/S radio, which may decrease the secretion of HBsAg[[108](#_ENREF_108),[109](#_ENREF_109)]. Deletions in the Pre-S2 region may be associated with antiviral-resistance, which is in turn linked to OBI. Mutations correspond to lamivudine (LMV)-resistance were commonly detected in OBIs[[110](#_ENREF_110)], and Pre-S2 deletion mutants were frequently found in patients with antiviral-resistance and proven to play a supportive role in the replication of LMV-resistant viruses by transfection analysis[[111](#_ENREF_111)].

***Pre-S/S insertion***

2 to 8 amino acids insertions have been observed between codons 121 and 124 located upstream of the “α” determinant in OBI patients from the Far East, which caused detection failure of HBsAg by conventional assays utilizing monoclonal and polyclonal antibodies[[112](#_ENREF_112)]. Insertions occurred at these sites strongly influence the binding efficiency of HBsAg antibodies and may affect the conformation of the “α” determinant as well as the subtype determinant d/y at aa122. In addition, insertions detected in the Pre-S/S gene in OBI patients may lead to frameshift mutations or stop codon mutations and interfere with HBsAg detection.

***Pre-S/S stop codon***

Stop codon mutations in Pre-S/S gene result in truncations of envelops proteins and may affect the expression and/or secretion of HBsAg. A stop codon mutation at aa216 in the C-terminus of HBsAg was observed in occult HBV/HIV co-infected patients, and displayed undetectable or extremely low level of HBsAg in transfection experiments[[73](#_ENREF_73)]. Other stop codon mutations at amino acid positions 61, 69, 181 *etc*. were also detected in OBI patients. These mutations may be correlated with failure in HBsAg detection but *in vivo* and *in vitro* studies are required to confirm this association[[113](#_ENREF_113)]. Furthermore, Pre-S/S gene overlaps with the RT region of P gene, and mutations correspond to antiviral-resistance in the RT domain commonly result in stop codon mutations in HBsAg and changed antigenicity and secretion of HBsAg[[114](#_ENREF_114)].

**C GENE MUTATIONS**

A1762T/G1764A double mutations in the BCP region and G1896A in the Pre-C region are the most frequently observed point substitutions in C gene. These mutations prevent the production of HBeAg and are linked to HCC[[115](#_ENREF_115)]. Genotypes C and D of HBV have been reported with relatively high mutation rate in BCP region[[116](#_ENREF_116)]. However, A1762T/G1764A and G1896A were not common in genotype D-infected OBI patients from Turkey and India[[117](#_ENREF_117),[118](#_ENREF_118)]. A study from Taiwan conducted on OBI related HCC and HBsAg-positive HCC patients found that common mutations such as A1762T/G1764A, G1896A，*etc*. that are common in HBsAg-positive HCC were not frequently detected in OBI related HCC patients[[119](#_ENREF_119)]. Therefore, point mutations in BCP/Pre-C in CHB may be not associated with OBI and required to be explored by further functional studies. Several deletion mutations in the BCP region such as nt1753-1772, nt1751-1770, nt1754-1771, *etc*. have been reported in OBIs, and variants containing deletions of nt1754-1771 reduced virion replication and expression levels of HBsAg and HBeAg (Figure 3)[[97](#_ENREF_97)]. The BCP region recruits initiators for the transcription of Pre-C mRNA and pregenomic (pg) RNA and is rich in AT content[[[120](#_ENREF_120),[121](#_ENREF_121)]. Deletion mutations in the BCP region may prevent transcription of pgRNA leading to reduction in HBV DNA replication and HBsAg expression. Moreover, BCP region overlaps with X gene and deletions in BCP region lead to truncated X protein, which also has an effect on virion replication and antigen expression[[122](#_ENREF_122)].

**X GENE MUTATIONS**

X gene is a regulatory gene and generates X protein made up of 146 to 154 aa. X protein acts as a transcription factor and trans-activates gene expression of HBV and several other viruses and cells[[123](#_ENREF_123)]. X gene harbors enhancer elements and the C promoter, and deletion mutations covering C promoter were frequently encountered in various HBV infections such as OBI, HBeAg-negative infection and so on[[124](#_ENREF_124)]. The C-terminal end of X protein is essential for the trans-activation function of X protein[[122](#_ENREF_122)]. 8-bp (nt1763-1770) and 20-bp deletion (nt1753-1772) mutations at the C-terminal end of X protein were frequently observed in OBIs, and variants containing these two deletions led to truncation of X protein and decrease in Pre-C promoter activity as well as secretion of HBsAg, HBeAg and HBcAg in transfected cell lines (Figure 3)[[125](#_ENREF_125),[126](#_ENREF_126)]. 8 nt deletions (nt1640-1647 or nt1770-1777) were frequently detected in occult HBV/HCV co-infected patients and exerted positive effect on HCV replication but negative effect on HBV replication[[127](#_ENREF_127),[128](#_ENREF_128)]. Besides, partial and large deletion mutations in X gene have been reported in OBIs in renal dialysis and HBV-vaccinated thalassemia patients[[129](#_ENREF_129)].

**P GENE MUTATIONS**

P gene overlaps S gene, thus mutations occur in one gene may affect the other gene. The RT region of P gene completely span S region, thus mutations resistant to nucleos(t)ide analogues (NAs) in RT region frequently lead to mutations of HBsAg (including stop codon mutations) and affect the antigenicity of HBsAg (Figure 3)[[114](#_ENREF_114),[130](#_ENREF_130)]. Transient selection of a V542I mutant in the HBV polymerase has been described in a CHB patient with prolonged administration of famciclovir. The mutation corresponded to a stop codon mutation at aa199 in S gene and transfection experiment demonstrated that full-length HBV genome harboring the mutation had a negative effect on replication capacity and failed to produce HBsAg[[131](#_ENREF_131)]. The rtA181T variant was frequently found in patients with adefovir (ADV)–resistance, corresponded to stop codon mutation at aaW172 in S gene (sW172\*) and led to truncation of 55 aa at the C-terminal end of HBsAg. The variant not only resulted in secretion deficiency of virion but also exerted dominant negative effect on virion secretion despite co-transfection with wild-type isolates[[132](#_ENREF_132)]. Other common antiviral-resistant mutations which lead to truncation of S proteins include entecavir (ETV)-resistant rtT184M corresponding to sL176\*, rtM204I (YIDD) both resistant to LMV and telbivudine (LdT) corresponding to sW196\* and so on[[114](#_ENREF_114)]. The rtM204V (YVDD), accompanied by rtV173L (corresponding to sI195M and sE164D) and/or rtL180M, were detected in both HBsAg-negative patients and HBsAg-positive patients untreated with LMV[[133](#_ENREF_133),[134](#_ENREF_134)]. Variants harboring YIDD or YVDD caused drastical reduction in virion replication capacity in transfection experiments[[135](#_ENREF_135)]. Some studies found that LMV-selected HBsAg protein changes including E164D, I195M and E164D/I195M significantly reduced the binding efficiency to anti-HBs, implying the potential to escape HBV vaccine like G145R[[133](#_ENREF_133)]. Point mutations in the RNase H domain of P gene were observed in vaccinated children with OBIs[[52](#_ENREF_52)]. *In vitro* studies demonstrated that RNase H region is essential for both RNA packaging and DNA synthesis and P gene of HBV and DHBV have similar biological properties, and point mutations in the RNase H region of duck hepatitis B virus such as L697Y, V719Y *etc*. led to deficiency of RNA packaging and significant reduction of DNA synthesis[[136](#_ENREF_136)].

Deletion mutations in P gene have been rarely reported. A 281-bp deletion (nt2068-2349) covering the start codon of P gene has been reported in genotype B infected OBIs but the relationship remains to be confirmed by functional studies[[137](#_ENREF_137)].

**NO OBI-RELEVANT MUTATIONS**

Mutations in the “α” determinant of S protein are “hot spots” of OBI related mutations, but some clinical reports demonstrated that no mutation was detected in the “α” determinant or the mutation rate of the “α” determinant in OBI group was not significantly different from HBsAg-positive infections[[31](#_ENREF_31)]. In some OBI patients, no mutation was detected in Pre-S/S gene[[117](#_ENREF_117)]. Moreover, no OBI-relevant mutation was found throughout the entire genome of HBV strains isolated from some OBI patients[[138](#_ENREF_138)]. As no OBI-relevant mutation was encountered in some cases of OBI and some mutations occurred in both OBIs and HBsAg-positive infections, some reports concluded that there were no OBI-specific mutations[[45](#_ENREF_45)]. Furthermore, *in vivo* and *in vitro* studies have demonstrated that some mutations identified in clinical reports did not interfere with HBV replication and expression or HBsAg secretion and were not really associated with OBI. In a recent study, we investigated a number of OBI patients with a family history of HBV infection by cloning and sequencing the Pre-S/S region of HBV DNA isolated from serum samples. Sequence comparison between OBI patients and their family members with CHB failed to identify common genetic variations that were specific for OBI[[139](#_ENREF_139)].

**PROBLEMS**

The mechanism of OBI is complex and remains to be clarified. Previous related studies are found with several limitations as follows: (1) It is difficult to amplify the full-length HBV genome due to the extremely low viral load in OBI patients and most clinical reports are limited to mutations in part of the viral genomes (mainly the S gene coding for HBsAg) while studies based on full-length HBV genomes are rare; (2) Most previous studies of OBI were clinical reports with limited case numbers and no comparable controls, and conclusions about some mutations were not consistent across reports; (3) Most mutations were not studied *in vivo* or *in vitro*, and some mutations occurred both in OBIs and HBsAg-positive infections; (4) Functional studies of mutations are mostly focused on the secretion, antigenicity or immunogenicity of HBsAg, while only a few of them addressed virion replication and secretion, and completely opposite conclusions may be drawn by studies on the same mutations depending on whether a fragment or the entire genome was used (data not available); (5) Most studies focused on individual mutations, and it remained to be explored whether multiple mutations interact with each other or whether there is secondary function; (6) HBV genotype and subgenotype were ignored in most studies; (7) There is a lack of suitable reference sequences for genotype and subgenotype of HBV and it is hard to determine whether some amino acid substitutions were genotype-specific or OBI-related[[140](#_ENREF_140)]; and (8) The levels of serum HBsAg in some OBI patients were fluctuant and it remains to be elucidated whether HBV methylation, glycosylation, acetylation or miRNA plays a role in this phenomenon.

Screening of OBI is strongly affected by the assays for detection of HBsAg and HBV DNA. For instance, the Abbott assay is highly sensitive for G145R detection. It is our opinion that multiple assays should be performed to verify the accuracy of the screening results and reduce false positive or false negative results. NAT of HBV is highly sensitive and able to detect extremely low levels of HBV DNA but has a potential risk of false-positive results due to quality-control problems. HBV NAT is still important for recognition of OBI in HBsAg-negative blood donations worldwide especially in high-endemic countries. However, NAT haven’t been implemented in most of these countries due to its high cost[[141](#_ENREF_141)]. In these countries, blood donations are screened by serological testing of HBsAg alone or combined with anti-HBc. In low-endemic regions of HBV or high-endemic regions of anti-HBc, anti-HBc testing may be not as effective as NAT[[142](#_ENREF_142)]. Anti-HBc screening is not capable to detect pre-seroconversion window period (WP) infections and anti-HBc assays based on radio immunoassay (RIA) or enzyme immunoassay (EIA) may suffer from false-positive results[[143](#_ENREF_143),[144](#_ENREF_144)]. Although liver biopsy is the best way for detecting OBI, it is hard to obtain liver tissue and standardized assays for it are not yet available[[145](#_ENREF_145)].

**CONCLUSION**

OBI is a special and complex form of HBV infection with worldwide distribution. Its prevalence significantly varied in terms of locations, detection assays and study population. The underlying mechanism of OBI is complex and unclear. Genetic variants may be relevant but still need to be studied *in vivo* and *in vitro*.

**ACKNOWLEDGMENTS**

We are deeply thankful to Dr. Meng-Ji Lu and Dr. Chun-Chen Wu for proof reading of the manuscript.

**REFERENCES**

1 **Summers J**, Mason WS. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. *Cell* 1982; **29**: 403-415 [PMID: 6180831]

2 **Okamoto H**, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. *Jpn J Exp Med* 1987; **57**: 231-236 [PMID: 3430800]

3 **Sterneck M**, Günther S, Gerlach J, Naoumov NV, Santantonio T, Fischer L, Rogiers X, Greten H, Williams R, Will H. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. *J Hepatol* 1997; **26**: 754-764 [PMID: 9126786]

4 **Kay A**, Zoulim F. Hepatitis B virus genetic variability and evolution. *Virus Res* 2007; **127**: 164-176 [PMID: 17383765 DOI: 10.1016/j.virusres.2007.02.021]

5 **Hoofnagle JH**, Seeff LB, Bales ZB, Zimmerman HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. *N Engl J Med* 1978; **298**: 1379-1383 [PMID: 652005 DOI: 10.1056/nejm197806222982502]

6 **Raimondo G**, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. *J Hepatol* 2008; **49**: 652-657 [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]

7 **Raimondo G**, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, Di Vita G, Scisca C, Squadrito G, Pollicino T. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. *J Hepatol* 2008; **48**: 743-746 [PMID: 18314221 DOI: 10.1016/j.jhep.2008.01.023]

8 **Walz A**, Wirth S, Hucke J, Gerner P. Vertical transmission of hepatitis B virus (HBV) from mothers negative for HBV surface antigen and positive for antibody to HBV core antigen. *J Infect Dis* 2009; **200**: 1227-1231 [PMID: 19751152 DOI: 10.1086/605698]

9 **Candotti D**, Allain JP. Transfusion-transmitted hepatitis B virus infection. *J Hepatol* 2009; **51**: 798-809 [PMID: 19615780 DOI: 10.1016/j.jhep.2009.05.020]

10 **Chemin I**, Trépo C. Clinical impact of occult HBV infections. *J Clin Virol* 2005; **34** Suppl 1: S15-S21 [PMID: 16461218]

11 **Wong DK**, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. *Hepatology* 2011; **54**: 829-836 [PMID: 21809355 DOI: 10.1002/hep.24551]

12 **Chemin I**, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevallier P, Mandrand B, Trépo C. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. *J Hepatol* 2001; **34**: 447-454 [PMID: 11322208]

13 **Pollicino T**, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. *Gastroenterology* 2004; **126**: 102-110 [PMID: 14699492]

14 **Westhoff TH**, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. *Blood* 2003; **102**: 1930 [PMID: 12930732 DOI: 10.1182/blood-2003-05-1403]

15 **Altfeld M**, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. *J Hepatol* 1998; **29**: 306-309 [PMID: 9722213]

16 **Kidd-Ljunggren K**, Simonsen O. Reappearance of hepatitis B 10 years after kidney transplantation. *N Engl J Med* 1999; **341**: 127-128 [PMID: 10409028 DOI: 10.1056/nejm199907083410213]

17 **Schmeltzer P**, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. *Dig Dis Sci* 2010; **55**: 3328-3335 [PMID: 20927592 DOI: 10.1007/s10620-010-1413-0]

18 **Hu KQ**. Occult hepatitis B virus infection and its clinical implications. *J Viral Hepat* 2002; **9**: 243-257 [PMID: 12081601]

19 **Yuen MF**, Lee CK, Wong DK, Fung J, Hung I, Hsu A, But DY, Cheung TK, Chan P, Yuen JC, Fung FK, Seto WK, Lin CK, Lai CL. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. *Gut* 2010; **59**: 1389-1393 [PMID: 20675695 DOI: 10.1136/gut.2010.209148]

20 **Zheng X**, Ye X, Zhang L, Wang W, Shuai L, Wang A, Zeng J, Candotti D, Allain JP, Li C. Characterization of occult hepatitis B virus infection from blood donors in China. *J Clin Microbiol* 2011; **49**: 1730-1737 [PMID: 21411575 DOI: 10.1128/jcm.00145-11]

21 **Seo DH**, Whang DH, Song EY, Kim HS, Park Q. Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. *Transfusion* 2011; **51**: 1840-1846 [PMID: 21332731 DOI: 10.1111/j.1537-2995.2010.03056.x]

22 **Satake M**, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. *Transfusion* 2007; **47**: 1197-1205 [PMID: 17581154 DOI: 10.1111/j.1537-2995.2007.01276.x]

23 **O'Brien SF**, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. *Transfusion* 2007; **47**: 1809-1815 [PMID: 17880605 DOI: 10.1111/j.1537-2995.2007.01396.x]

24 **Hollinger FB**. Hepatitis B virus infection and transfusion medicine: science and the occult. *Transfusion* 2008; **48**: 1001-1026 [PMID: 18454738 DOI: 10.1111/j.1537-2995.2008.01701.x]

25 **Hofer M**, Joller-Jemelka HI, Grob PJ, Lüthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. *Eur J Clin Microbiol Infect Dis* 1998; **17**: 6-13 [PMID: 9512175]

26 **Núñez M**, Ríos P, Pérez-Olmeda M, Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. *AIDS* 2002; **16**: 2099-2101 [PMID: 12370518]

27 **Cacciola I**, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. *N Engl J Med* 1999; **341**: 22-26 [PMID: 10387938 DOI: 10.1056/nejm199907013410104]

28 **De Maria N**, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. *Am J Gastroenterol* 2000; **95**: 3529-3536 [PMID: 11151889 DOI: 10.1111/j.1572-0241.2000.03371.x]

29 **Gutiérrez-García ML**, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. *World J Gastroenterol* 2011; **17**: 1538-1542 [PMID: 21472117 DOI: 10.3748/wjg.v17.i12.1538]

30 **Minuk GY**, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. *Hepatology* 2004; **40**: 1072-1077 [PMID: 15486926 DOI: 10.1002/hep.20435]

31 **Chan HL**, Tsang SW, Leung NW, Tse CH, Hui Y, Tam JS, Chan FK, Sung JJ. Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. *Am J Gastroenterol* 2002; **97**: 1211-1215 [PMID: 12014730 DOI: 10.1111/j.1572-0241.2002.05706.x]

32 **Fang Y**, Shang QL, Liu JY, Li D, Xu WZ, Teng X, Zhao HW, Fu LJ, Zhang FM, Gu HX. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. *J Infect* 2009; **58**: 383-388 [PMID: 19329189 DOI: 10.1016/j.jinf.2009.02.013]

33 **Ireland JH**, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GK, Carman WF. Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. *Hepatology* 2000; **31**: 1176-1182 [PMID: 10796895 DOI: 10.1053/he.2000.6407]

34 **Weber B**. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. *J Med Virol* 2006; **78** Suppl 1: S59-S65 [PMID: 16622880 DOI: 10.1002/jmv.20610]

35 **Kaneko S**, Miller RH, Feinstone SM, Unoura M, Kobayashi K, Hattori N, Purcell RH. Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. *Proc Natl Acad Sci USA* 1989; **86**: 312-316 [PMID: 2643103]

36 **Roth WK**, Weber M, Seifried E. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. *Lancet* 1999; **353**: 359-363 [PMID: 9950441 DOI: 10.1016/s0140-6736(98)06318-1]

37 **Zerbini A**, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P, Giuberti T, Orlandini A, Raffa G, Pollicino T, Raimondo G, Ferrari C, Missale G. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. *Gastroenterology* 2008; **134**: 1470-1481 [PMID: 18355815 DOI: 10.1053/j.gastro.2008.02.017]

38 **Levrero M**, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. *J Hepatol* 2009; **51**: 581-592 [PMID: 19616338 DOI: 10.1016/j.jhep.2009.05.022]

39 **Zhang X**, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. *Front Genet* 2013; **4**: 202 [PMID: 24133502 DOI: 10.3389/fgene.2013.00202]

40 **Pollicino T**, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. *Hepatology* 2007; **45**: 277-285 [PMID: 17256766 DOI: 10.1002/hep.21529]

41 **Lada O**, Benhamou Y, Poynard T, Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. *J Virol* 2006; **80**: 2968-2975 [PMID: 16501106 DOI: 10.1128/jvi.80.6.2968-2975.2006]

42 **Zhang JM**, Xu Y, Wang XY, Yin YK, Wu XH, Weng XH, Lu M. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. *Clin Infect Dis* 2007; **44**: 1161-1169 [PMID: 17407033 DOI: 10.1086/513200]

43 **Zanella I**, Rossini A, Domenighini D, Albertini A, Cariani E. Real-time quantitation of hepatitis B virus (HBV) DNA in tumorous and surrounding tissue from patients with hepatocellular carcinoma. *J Med Virol* 2002; **68**: 494-499 [PMID: 12376956 DOI: 10.1002/jmv.10243]

44 **Kaur P**, Paliwal A, Durantel D, Hainaut P, Scoazec JY, Zoulim F, Chemin I, Herceg Z. DNA methylation of hepatitis B virus (HBV) genome associated with the development of hepatocellular carcinoma and occult HBV infection. *J Infect Dis* 2010; **202**: 700-704 [PMID: 20653444 DOI: 10.1086/655398]

45 **Vivekanandan P**, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. *Clin Infect Dis* 2008; **46**: 1227-1236 [PMID: 18444860 DOI: 10.1086/529437]

46 **Bläckberg J**, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. *J Hepatol* 2000; **33**: 992-997 [PMID: 11131464]

47 **Mason A**, Yoffe B, Noonan C, Mearns M, Campbell C, Kelley A, Perrillo RP. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. *Hepatology* 1992; **16**: 36-41 [PMID: 1618481]

48 **Michalak TI**. Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. *Immunol Rev* 2000; **174**: 98-111 [PMID: 10807510]

49 **Mulrooney-Cousins PM**, Michalak TI. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. *World J Gastroenterol* 2007; **13**: 5682-5686 [PMID: 17963292 DOI: 10.3748/wjg.v13.i43.5682]

50 **Cabrerizo M**, Bartolomé J, Caramelo C, Barril G, Carreno V. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. *Hepatology* 2000; **32**: 116-123 [PMID: 10869298 DOI: 10.1053/jhep.2000.8541]

51 **Colson P**, Borentain P, Coso D, Motte A, Aurran-Schleinitz T, Charbonnier A, Stoppa AM, Chabannon C, Serrero M, Bertrand J, Barlesi F, Serratrice J, Portal I, Botta-Fridlund D, Tamalet C, Gerolami R. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. *Virology* 2015; **484**: 354-363 [PMID: 26186574 DOI: 10.1016/j.virol.2015.06.017]

52 **Shahmoradi S**, Yahyapour Y, Mahmoodi M, Alavian SM, Fazeli Z, Jazayeri SM. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. *J Hepatol* 2012; **57**: 515-521 [PMID: 22617152 DOI: 10.1016/j.jhep.2012.04.021]

53 **Mu SC**, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. *J Hepatol* 2009; **50**: 264-272 [PMID: 19070923 DOI: 10.1016/j.jhep.2008.09.017]

54 **Ramezani A**, Banifazl M, Mamishi S, Sofian M, Eslamifar A, Aghakhani A. The influence of human leukocyte antigen and IL-10 gene polymorphisms on hepatitis B virus outcome. *Hepat Mon* 2012; **12**: 320-325 [PMID: 22783343 DOI: 10.5812/hepatmon.6094]

55 **Askari A**, Hassanshahi GH, Ghalebi SR, Jafarzadeh A, Mohit M, Hajghani M, Kazemi Arababadi M. Intensity of HLA-A2 Expression Significantly Decreased in Occult Hepatitis B Infection. *Jundishapur J Microbiol* 2014; **7**: e10298 [PMID: 25371796 DOI: 10.5812/jjm.10298]

56 **Arababadi MK**, Pourfathollah AA, Jafarzadeh A, Hassanshahi G. Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients. *Hepat Mon* 2010; **10**: 31-35 [PMID: 22308123]

57 **Ahmadabadi BN**, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D. The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. *Inflammation* 2012; **35**: 818-821 [PMID: 21901441 DOI: 10.1007/s10753-011-9381-x]

58 **Zhang X**, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. *Hepatology* 2011; **53**: 1476-1485 [PMID: 21520166 DOI: 10.1002/hep.24195]

59 **Chen Y**, Li L, Zhou Z, Wang N, Zhang CY, Zen K. A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection. *Med Microbiol Immunol* 2012; **201**: 389-395 [PMID: 22392036 DOI: 10.1007/s00430-011-0223-0]

60 **Pollicino T**, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. *Gastroenterology* 2006; **130**: 823-837 [PMID: 16530522 DOI: 10.1053/j.gastro.2006.01.001]

61 **Khattab E**, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. *J Clin Virol* 2005; **33**: 150-157 [PMID: 15911431 DOI: 10.1016/j.jcv.2004.10.016]

62 **Sagnelli E**, Coppola N, Scolastico C, Filippini P, Santantonio T, Stroffolini T, Piccinino F. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. *Hepatology* 2000; **32**: 1106-1110 [PMID: 11050062 DOI: 10.1053/jhep.2000.19288]

63 **Shih CM**, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. *J Virol* 1993; **67**: 5823-5832 [PMID: 8396658]

64 **Seeger C**, Mason WS. Hepatitis B virus biology. *Microbiol Mol Biol Rev* 2000; **64**: 51-68 [PMID: 10704474]

65 **Hsu CW**, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. *Hepatology* 2011; **54**: 101-108 [PMID: 21503942 DOI: 10.1002/hep.24363]

66 **Huang CH**, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, Yeh SH, Yu H, Xue Y, Chen YX, Liu PG, Ge SX, Zhang J, Xia NS. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. *J Hepatol* 2012; **57**: 720-729 [PMID: 22634131 DOI: 10.1016/j.jhep.2012.05.009]

67 **Kalinina T**, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. *Hepatology* 2003; **38**: 1274-1281 [PMID: 14578867 DOI: 10.1053/jhep.2003.50484]

68 **Norder H**, Couroucé AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. *J Gen Virol* 1992; **73 ( Pt 12)**: 3141-3145 [PMID: 1469353]

69 **Tian Y**, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D. The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. *J Clin Microbiol* 2007; **45**: 2971-2978 [PMID: 17609325 DOI: 10.1128/jcm.00508-07]

70 **Bes M**, Vargas V, Piron M, Casamitjana N, Esteban JI, Vilanova N, Pinacho A, Quer J, Puig L, Guardia J, Sauleda S. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. *J Hepatol* 2012; **56**: 765-774 [PMID: 22173156 DOI: 10.1016/j.jhep.2011.11.011]

71 **Carman WF**, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. *Lancet* 1995; **345**: 1406-1407 [PMID: 7539089]

72 **Carman WF**, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. *Lancet* 1990; **336**: 325-329 [PMID: 1697396]

73 **Märschenz S**, Endres AS, Brinckmann A, Heise T, Kristiansen G, Nürnberg P, Krüger DH, Günther S, Meisel H. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. *Gastroenterology* 2006; **131**: 765-780 [PMID: 16952546 DOI: 10.1053/j.gastro.2006.07.008]

74 **Chaudhuri V**, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. *Gastroenterology* 2004; **127**: 1356-1371 [PMID: 15521005]

75 **Qiu J**, Qin B, Rayner S, Wu CC, Pei RJ, Xu S, Wang Y, Chen XW. Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. *Virol Sin* 2011; **26**: 131-138 [PMID: 21468936 DOI: 10.1007/s12250-011-3190-0]

76 **Mello FC**, Martel N, Gomes SA, Araujo NM. Expression of Hepatitis B Virus Surface Antigen Containing Y100C Variant Frequently Detected in Occult HBV Infection. *Hepat Res Treat* 2011; **2011**: 695859 [PMID: 21331286 DOI: 10.1155/2011/695859]

77 **Svicher V**, Cento V, Bernassola M, Neumann-Fraune M, Van Hemert F, Chen M, Salpini R, Liu C, Longo R, Visca M, Romano S, Micheli V, Bertoli A, Gori C, Ceccherini-Silberstein F, Sarrecchia C, Andreoni M, Angelico M, Ursitti A, Spanò A, Zhang JM, Verheyen J, Cappiello G, Perno CF. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. *Antiviral Res* 2012; **93**: 86-93 [PMID: 22086128 DOI: 10.1016/j.antiviral.2011.10.022]

78 **Ito K**, Qin Y, Guarnieri M, Garcia T, Kwei K, Mizokami M, Zhang J, Li J, Wands JR, Tong S. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. *J Virol* 2010; **84**: 12850-12861 [PMID: 20881037 DOI: 10.1128/jvi.01499-10]

79 **Kwei K**, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, Tong S. Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. *J Virol* 2013; **87**: 2352-2357 [PMID: 23221548 DOI: 10.1128/jvi.02701-12]

80 **El Chaar M**, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. *Hepatology* 2010; **52**: 1600-1610 [PMID: 20815025 DOI: 10.1002/hep.23886]

81 **Wu C**, Deng W, Deng L, Cao L, Qin B, Li S, Wang Y, Pei R, Yang D, Lu M, Chen X. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. *J Virol* 2012; **86**: 4658-4669 [PMID: 22301154 DOI: 10.1128/jvi.06353-11]

82 **Wu C**, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. *J Gen Virol* 2010; **91**: 483-492 [PMID: 19812261 DOI: 10.1099/vir.0.012740-0]

83 **Seddigh-Tonekaboni S**, Waters JA, Jeffers S, Gehrke R, Ofenloch B, Horsch A, Hess G, Thomas HC, Karayiannis P. Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. *J Med Virol* 2000; **60**: 113-121 [PMID: 10596008]

84 **Kim KH**, Chang HY, Park JY, Park ES, Park YK, Han KH, Ahn SH. Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. *Clin Mol Hepatol* 2014; **20**: 251-260 [PMID: 25320728 DOI: 10.3350/cmh.2014.20.3.251]

85 **Schories M**, Peters T, Rasenack J. Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection. *J Hepatol* 2000; **33**: 799-811 [PMID: 11097490]

86 **Martin CM**, Welge JA, Rouster SD, Shata MT, Sherman KE, Blackard JT. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. *J Viral Hepat* 2012; **19**: 716-723 [PMID: 22967103 DOI: 10.1111/j.1365-2893.2012.01595.x]

87 **Tang JH**, Yeh CT, Chen TC, Hsieh SY, Chu CM, Liaw YF. Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. *J Infect Dis* 1998; **178**: 866-869 [PMID: 9728561]

88 **Vigerust DJ**, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. *Trends Microbiol* 2007; **15**: 211-218 [PMID: 17398101 DOI: 10.1016/j.tim.2007.03.003]

89 **Julithe R**, Abou-Jaoudé G, Sureau C. Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies. *J Virol* 2014; **88**: 9049-9059 [PMID: 24899172 DOI: 10.1128/jvi.01161-14]

90 **Yu DM**, Li XH, Mom V, Lu ZH, Liao XW, Han Y, Pichoud C, Gong QM, Zhang DH, Zhang Y, Deny P, Zoulim F, Zhang XX. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. *J Hepatol* 2014; **60**: 515-522 [PMID: 24239777 DOI: 10.1016/j.jhep.2013.11.004]

91 **Garcia T**, Li J, Sureau C, Ito K, Qin Y, Wands J, Tong S. Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. *J Virol* 2009; **83**: 11152-11165 [PMID: 19706705 DOI: 10.1128/jvi.00905-09]

92 **Kozak M**. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. *Cell* 1986; **44**: 283-292 [PMID: 3943125]

93 **Hass M**, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. *Hepatology* 2005; **42**: 93-103 [PMID: 15962285 DOI: 10.1002/hep.20748]

94 **van Hemert FJ**, Zaaijer HL, Berkhout B, Lukashov VV. Occult hepatitis B infection: an evolutionary scenario. *Virol J* 2008; **5**: 146 [PMID: 19077239 DOI: 10.1186/1743-422x-5-146]

95 **Melegari M**, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. *J Virol* 1997; **71**: 5449-5454 [PMID: 9188617]

96 **Gerner PR**, Friedt M, Oettinger R, Lausch E, Wirth S. The hepatitis B virus seroconversion to anti-HBe is frequently associated with HBV genotype changes and selection of preS2-defective particles in chronically infected children. *Virology* 1998; **245**: 163-172 [PMID: 9614877 DOI: 10.1006/viro.1998.9126]

97 **Fang Y**, Teng X, Xu WZ, Li D, Zhao HW, Fu LJ, Zhang FM, Gu HX. Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. *J Med Virol* 2009; **81**: 826-835 [PMID: 19319940 DOI: 10.1002/jmv.21463]

98 **Raney AK**, Le HB, McLachlan A. Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor. *J Virol* 1992; **66**: 6912-6921 [PMID: 1331502]

99 **Lu CC**, Yen TS. Activation of the hepatitis B virus S promoter by transcription factor NF-Y via a CCAAT element. *Virology* 1996; **225**: 387-394 [PMID: 8918925 DOI: 10.1006/viro.1996.0613]

100 **Bock CT**, Kubicka S, Manns MP, Trautwein C. Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factor. *Hepatology* 1999; **29**: 1236-1247 [PMID: 10094970 DOI: 10.1002/hep.510290426]

101 **Bock CT**, Tillmann HL, Maschek HJ, Manns MP, Trautwein C. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. *Gastroenterology* 1997; **113**: 1976-1982 [PMID: 9394738]

102 **Sengupta S**, Rehman S, Durgapal H, Acharya SK, Panda SK. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. *J Med Virol* 2007; **79**: 220-228 [PMID: 17245717 DOI: 10.1002/jmv.20790]

103 **Xu Z**, Yen TS. Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. *J Virol* 1996; **70**: 133-140 [PMID: 8523517]

104 **Ganem D**. Assembly of hepadnaviral virions and subviral particles. *Curr Top Microbiol Immunol* 1991; **168**: 61-83 [PMID: 1893779]

105 **Bruss V**. Revisiting the cytopathic effect of hepatitis B virus infection. *Hepatology* 2002; **36**: 1327-1329 [PMID: 12447854 DOI: 10.1053/jhep.2002.37351]

106 **Itoh Y**, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. *Proc Natl Acad Sci USA* 1986; **83**: 9174-9178 [PMID: 3466181]

107 **Bruss V**, Ganem D. The role of envelope proteins in hepatitis B virus assembly. *Proc Natl Acad Sci USA* 1991; **88**: 1059-1063 [PMID: 1992457]

108 **Pollicino T**, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. *J Hepatol* 2014; **61**: 408-417 [PMID: 24801416 DOI: 10.1016/j.jhep.2014.04.041]

109 **Kim H**, Lee SA, Kim DW, Lee SH, Kim BJ. Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. *PLoS One* 2013; **8**: e54486 [PMID: 23349904 DOI: 10.1371/journal.pone.0054486]

110 **Besisik F**, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioglu A, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. *J Hepatol* 2003; **38**: 506-510 [PMID: 12663244]

111 **Zhang D**, Dong P, Zhang K, Deng L, Bach C, Chen W, Li F, Protzer U, Ding H, Zeng C. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. *BMC Microbiol* 2012; **12**: 307 [PMID: 23272650 DOI: 10.1186/1471-2180-12-307]

112 **Hou J**, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, Zhou F, Waters J, Karayiannis P, Luo K. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. *Hepatology* 2001; **34**: 1027-1034 [PMID: 11679975 DOI: 10.1053/jhep.2001.28708]

113 **Cassini R**, De Mitri MS, Gibellini D, Urbinati L, Bagaglio S, Morsica G, Domenicali M, Verucchi G, Bernardi M. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. *J Viral Hepat* 2013; **20**: 42-49 [PMID: 23231083 DOI: 10.1111/j.1365-2893.2012.01623.x]

114 **Zoulim F**, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology* 2009; **137**: 1593-608.e1-2 [PMID: 19737565 DOI: 10.1053/j.gastro.2009.08.063]

115 **Yang HI**, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst* 2008; **100**: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]

116 **Liu CJ**, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. *Semin Liver Dis* 2013; **33**: 97-102 [PMID: 23749665 DOI: 10.1055/s-0033-1345716]

117 **Pinarbasi B**, Onel D, Cosan F, Akyuz F, Dirlik N, Cakaloglu Y, Badur S, Besisik F, Demir K, Okten A, Kaymakoglu S. Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey. *Liver Int* 2009; **29**: 227-230 [PMID: 18662283 DOI: 10.1111/j.1478-3231.2008.01809.x]

118 **Chandra PK**, Biswas A, Datta S, Banerjee A, Panigrahi R, Chakrabarti S, De BK, Chakravarty R. Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection. *J Viral Hepat* 2009; **16**: 749-756 [PMID: 19457142 DOI: 10.1111/j.1365-2893.2009.01129.x]

119 **Chen CH**, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. *Int J Cancer* 2009; **125**: 621-629 [PMID: 19431214 DOI: 10.1002/ijc.24416]

120 **Okamoto H**, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. *J Virol* 1994; **68**: 8102-8110 [PMID: 7966600]

121 **López-Cabrera M**, Letovsky J, Hu KQ, Siddiqui A. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein. *Proc Natl Acad Sci USA* 1990; **87**: 5069-5073 [PMID: 2367525]

122 **Arii M**, Takada S, Koike K. Identification of three essential regions of hepatitis B virus X protein for trans-activation function. *Oncogene* 1992; **7**: 397-403 [PMID: 1549357]

123 **Colgrove R**, Simon G, Ganem D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. *J Virol* 1989; **63**: 4019-4026 [PMID: 2788226]

124 **Wang Y**, Chen P, Wu X, Sun AL, Wang H, Zhu YA, Li ZP. A new enhancer element, ENII, identified in the X gene of hepatitis B virus. *J Virol* 1990; **64**: 3977-3981 [PMID: 2370684]

125 **Moriyama K**. Reduced antigen production by hepatitis B virus harbouring nucleotide deletions in the overlapping X gene and precore-core promoter. *J Gen Virol* 1997; **78 ( Pt 6)**: 1479-1486 [PMID: 9191946]

126 **Laskus T**, Rakela J, Tong MJ, Nowicki MJ, Mosley JW, Persing DH. Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. *J Hepatol* 1994; **20**: 837-841 [PMID: 7930487]

127 **Fukuda R**, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, Uchida Y, Ihihara S, Akagi S, Watanabe M, Kinoshita Y. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. *J Med Virol* 1999; **58**: 201-207 [PMID: 10447413]

128 **Uchida T**, Kaneita Y, Gotoh K, Kanagawa H, Kouyama H, Kawanishi T, Mima S. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. *J Med Virol* 1997; **52**: 399-405 [PMID: 9260688]

129 **Feitelson M**, Lega L, Guo J, Resti M, Rossi ME, Azzari C, Blumberg BS, Vierucci A. Pathogenesis of posttransfusion viral hepatitis in children with beta-thalassemia. *Hepatology* 1994; **19**: 558-568 [PMID: 8119679]

130 Zhang ZH, Deng WY, Lu MJ, Yang DL. Genetic variation and significance of hepatitis B surface antigen. J Clin Hepatol 2013; 29: 810-815 [DOI: 10.3969/j.issn.1001-5256.2013.11.003]

131 **Pichoud C**, Seignères B, Wang Z, Trépo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. *Hepatology* 1999; **29**: 230-237 [PMID: 9862871 DOI: 10.1002/hep.510290119]

132 **Warner N**, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172\* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. *Hepatology* 2008; **48**: 88-98 [PMID: 18537180 DOI: 10.1002/hep.22295]

133 **Torresi J**, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. *Virology* 2002; **293**: 305-313 [PMID: 11886250 DOI: 10.1006/viro.2001.1246]

134 **Motta JS**, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis. *J Gastroenterol Hepatol* 2010; **25**: 101-106 [PMID: 19817965 DOI: 10.1111/j.1440-1746.2009.05972.x]

135 **Melegari M**, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. *Hepatology* 1998; **27**: 628-633 [PMID: 9462667 DOI: 10.1002/hep.510270243]

136 **Chen Y**, Robinson WS, Marion PL. Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis. *J Virol* 1994; **68**: 5232-5238 [PMID: 8035519]

137 **Chen SJ**, Zhao YX, Fang Y, Xu WZ, Ma YX, Song ZW, Teng X, Gu HX. Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection. *Virus Res* 2012; **163**: 197-201 [PMID: 21963662 DOI: 10.1016/j.virusres.2011.09.029]

138 **Raimondo G**, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. *Semin Immunopathol* 2013; **35**: 39-52 [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7]

139 **Zhang Z**, Zhang L, Dai Y, Jin L, Sun B, Su Q, Li X. Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infection. *J Med Virol* 2015; **87**: 1890-1898 [PMID: 25964194 DOI: 10.1002/jmv.24245]

140 **Zhang ZH**, Zhang L, Lu MJ, Yang DL, Li X. [Establishment of reference sequences of hepatitis B virus genotype B and C in China]. *Zhonghua Gan Zang Bing Za Zhi* 2009; **17**: 891-895 [PMID: 20038328]

141 **Roth WK**, Busch MP, Schuller A, Ismay S, Cheng A, Seed CR, Jungbauer C, Minsk PM, Sondag-Thull D, Wendel S, Levi JE, Fearon M, Delage G, Xie Y, Jukic I, Turek P, Ullum H, Tefanova V, Tilk M, Reimal R, Castren J, Naukkarinen M, Assal A, Jork C, Hourfar MK, Michel P, Offergeld R, Pichl L, Schmidt M, Schottstedt V, Seifried E, Wagner F, Weber-Schehl M, Politis C, Lin CK, Tsoi WC, O'Riordan J, Gottreich A, Shinar E, Yahalom V, Velati C, Satake M, Sanad N, Sisene I, Bon AH, Koppelmann M, Flanagan P, Flesland O, Brojer E, Lętowska M, Nascimento F, Zhiburt E, Chua SS, Teo D, Stezinar SL, Vermeulen M, Reddy R, Park Q, Castro E, Eiras A, Gonzales Fraile I, Torres P, Ekermo B, Niederhauser C, Chen H, Oota S, Brant LJ, Eglin R, Jarvis L, Mohabir L, Brodsky J, Foster G, Jennings C, Notari E, Stramer S, Kessler D, Hillyer C, Kamel H, Katz L, Taylor C, Panzer S, Reesink HW. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. *Vox Sang* 2012; **102**: 82-90 [PMID: 21933190 DOI: 10.1111/j.1423-0410.2011.01506.x]

142 **Allain JP**. Occult hepatitis B virus infection: implications in transfusion. *Vox Sang* 2004; **86**: 83-91 [PMID: 15023176 DOI: 10.1111/j.0042-9007.2004.00406.x]

143 **Torbenson M**, Thomas DL. Occult hepatitis B. *Lancet Infect Dis* 2002; **2**: 479-486 [PMID: 12150847]

144 **Weber B**. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. *Expert Rev Mol Diagn* 2005; **5**: 75-91 [PMID: 15723594 DOI: 10.1586/14737159.5.1.75]

145 **Hollinger FB**, Sood G. Occult hepatitis B virus infection: a covert operation. *J Viral Hepat* 2010; **17**: 1-15 [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x]

**P-Reviewer:** Bock CT, Georgopoulou u, Stalke p **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**



**Figure 1 Comparison of the amino acid sequences of the 226aa hepatitis B virus, hepatitis B virus surface antigen between occult hepatitis B virus infections and controls.** Amino acid substitutions are indicated with one-letter codes. Mutations have been identified in occult hepatitis B virus infections group and control group are in red and black, respectively. Mutations have been detected in both groups are in blue. Black dots denote amino acid identity with any of the reference strains of genotype A to H retrieved from GenBank (accession numbers: A, X02763; Ba, D00330; Bc, GQ205440; Bj, AB073858; C1, KM999990; C2, KM999991; D, X02496; E, X75657; F, X69798; G, AF160501; H, AY090454). Genotype-specific substitutions are listed. CON indicates control.



**Figure 2 Secondary structure of the major hydrophilic region of the hepatitis B virus, hepatitis B virus surface antigen.** Mutations have been confirmed by functional studies to exert negative effects on antigenicity of hepatitis B virus surface antigen (HBsAg) are shown in green and red circles. Red circles with the △ symbol denote multiple kinds of amino acid substitutions being substantiated to negatively correlate with HBsAg antigenicity at some sites. The # symbol indicates multiple genotype-specific substitutions. The numbers denotes amino acid sites.



**Figure 3 Mutations in X, P and C genes of hepatitis B virus have been substantiated in association with the occurrence of occult hepatitis B virus infections by *in vivo* and *in vitro* studies.** Plus and minus strands are denoted by + and –, respectively.

**Table 1 Summary of hepatitis B virus surface antigen variants involved in functional studies**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variants** | **Source** | **Model** | **Antigenicity** | **Immuno**  **-genicity** | **HBsAg Intra-** | **HBsAg**  **Extra-** | **Viral replication**  **/secretion** | **References** |
| W741 | CHB | Huh7 | L |  | L | L |  | [[65](#_ENREF_65)] |
| M75T |  | Huh7 |  |  | ↑ | ↓ | ↓2 | [[75](#_ENREF_75)] |
| Y100C | OBI | Huh7 | ↑ |  |  |  |  | [[76](#_ENREF_76)] |
| Y100S | OBI | Huh7 | L |  |  |  |  | [[77](#_ENREF_77)] |
| I110M |  | Huh7 |  |  |  |  | L3 | [[78](#_ENREF_78)] |
| T114R |  | Huh7 |  |  |  |  | ↓3 | [[79](#_ENREF_79)] |
| T115A |  | Huh7 |  |  |  |  | ↓3 | [[79](#_ENREF_79)] |
| T116N | OBI | Huh7 | ↓ |  |  |  |  | [[77](#_ENREF_77)] |
| G119E |  | Huh7 |  |  |  | ↓ | ↓3 | [[78](#_ENREF_78)] |
| G119R | OBI | Huh7/mice | ↓ |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| P120T | OBI | Huh7/mice | ↓ |  |  |  |  | [[66](#_ENREF_66)] |
| P120T |  | Huh7 |  |  |  | ↓ |  | [[79](#_ENREF_79)] |
| C121S |  | HepG2/Hela | ↓ |  | ↓ | ↓ |  | [[69](#_ENREF_69)] |
| C1211 | OBI | Pichia | ↓or L |  |  |  |  | [[80](#_ENREF_80)] |
| C121A |  | Huh7 |  |  |  | ↓ | ↓ or L3 | [[79](#_ENREF_79)] |
| K122I |  | HepG2/Hela | ↓ |  | ↓ | ↓ |  | [[69](#_ENREF_69)] |
| K122I |  | Huh7 | ↓ | ↓ | ↓ | ↓ |  | [[81](#_ENREF_81)] |
| K122I |  | Huh7/Hela | ↓or L | ↓ | ↓ | ↓ |  | [[82](#_ENREF_82)] |
| R122P | OBI | Huh7 | ↓ |  |  |  |  | [[77](#_ENREF_77)] |
| T123N |  | HepG2/Hela | ↓ |  | ↓ | ↓ |  | [[69](#_ENREF_69)] |
| T123N |  | Huh7/Hela | ↓or L |  |  |  | ↓3 | [[82](#_ENREF_82)] |
| C1241 | OBI | Pichia | ↓or L |  |  |  |  | [[80](#_ENREF_80)] |
| C124A |  | Huh7 |  |  |  | ↓ | ↓ or L3 | [[79](#_ENREF_79)] |
| C124R | OBI | Huh7/mice | ↓ |  |  |  | ↓3 | [[66](#_ENREF_66)] |
| C124Y | OBI | Huh7/mice | ↓ |  |  |  | ↓3 | [[66](#_ENREF_66)] |
| T125A | CHB | Huh7 | ↓ |  |  | ↓ |  | [[65](#_ENREF_65)] |
| I126S | OBI | Huh7/mice |  |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| P127S |  | Huh7 |  |  |  |  | ↓3 | [[79](#_ENREF_79)] |
| Q129H |  | Huh7 |  |  |  |  | ↓3 | [[79](#_ENREF_79)] |
| Q129R | OBI | Huh7/mice |  |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| G130R |  | Huh7 |  |  |  |  | L3 | [[79](#_ENREF_79)] |
| T131I |  | Yeast | ↓ |  |  |  |  | [[83](#_ENREF_83)] |
| M133T4 |  | Huh7 |  |  |  |  |  | [[78](#_ENREF_78)] |
| S136P | OBI | Huh7/mice |  |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| C1371 | OBI | Pichia | ↓or L |  |  |  |  | [[80](#_ENREF_80)] |
| C138Y |  | Huh7 |  |  |  | ↓ | L3 | [[79](#_ENREF_79)] |
| C139R | CHB | HepG2 | ↓ |  |  |  |  | [[84](#_ENREF_84)] |
| C139R | OBI | Huh7/mice | ↓ |  |  |  | ↓3 | [[66](#_ENREF_66)] |
| T140I | OBI | Huh7/mice |  |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| K141E | OBI | Huh7/mice | ↓ |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| K141E |  | Huh7 |  |  |  | ↓ | ↓3 | [[79](#_ENREF_79)] |
| K141E |  | Yeast | ↓ |  |  |  |  | [[83](#_ENREF_83)] |
| P142S |  | Yeast | ↓ |  |  |  |  | [[83](#_ENREF_83)] |
| P142S |  | Huh7 |  |  |  | ↓ |  | [[79](#_ENREF_79)] |
| P142A | KT | Huh7 | ↓ |  |  |  |  | [[85](#_ENREF_85)] |
| D144V | KT | Huh7 | ↓ |  |  |  |  | [[85](#_ENREF_85)] |
| D144A | OBI | Huh7/mice | ↓ |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| D144G |  | Huh7 |  |  |  | ↓ | L3 | [[79](#_ENREF_79)] |
| D144E | LC | HepG2 | ↓ |  |  |  |  | [[84](#_ENREF_84)] |
| G145R |  | Yeast | ↓ |  |  |  |  | [[83](#_ENREF_83)] |
| G145R |  | HepG2/Hela | ↓ |  | ↓ | ↓ |  | [[69](#_ENREF_69)] |
| G145R | LT | Huh7 |  |  |  |  | ↓3 | [[67](#_ENREF_67)] |
| G145R |  | Huh7 | ↓ | ↓ |  | ↓ |  | [[81](#_ENREF_81)] |
| G145R |  | Huh7 |  |  |  | ↓ |  | [[79](#_ENREF_79)] |
| G145R | OBI | Huh7/mice | ↓ |  | ↑ | ↓ | ↓3 | [[66](#_ENREF_66)] |
| G145A | OBI | Huh7/mice | ↓ |  |  |  |  | [[66](#_ENREF_66)] |
| G145A | OBI | Huh7/HepG2 | ↓ |  | ↑ | ↓ |  | [[83](#_ENREF_83)] |
| G145A |  | Yeast | ↓ |  |  |  |  | [[81](#_ENREF_81)] |
| G145W |  | Huh7 |  | ↓ |  | ↓ |  | [[81](#_ENREF_81)] |
| G145I |  | Huh7 | ↓ | ↓ |  |  |  | [[81](#_ENREF_81)] |
| G145P |  | Huh7 | ↓ |  |  |  |  | [[81](#_ENREF_81)] |
| G145N |  | Huh7 | ↓ |  |  |  |  | [[81](#_ENREF_81)] |
| G145D |  | Huh7 | ↓ |  |  |  |  | [[81](#_ENREF_81)] |
| G145E |  | Huh7 |  | ↓ |  |  |  | [[79](#_ENREF_79)] |
| N146S |  | Huh7 |  |  |  |  | L3 | [[79](#_ENREF_79)] |
| C147A |  | Huh7 |  |  |  |  | ↓ or L3 | [[79](#_ENREF_79)] |
| C147R |  | Huh7 |  |  |  | ↓ | ↓3 | [[79](#_ENREF_79)] |
| C149A |  | Huh7 |  |  |  | ↓ | ↓ or L3 | [[79](#_ENREF_79)] |
| C149R |  | Huh7 |  |  |  | ↓ | L3 | [[79](#_ENREF_79)] |
| A159G |  | Huh7/Hela | ↓ | ↓ |  |  | ↓3 | [[82](#_ENREF_82)] |
| K160N |  | Huh7/Hela | ↓ | ↑5 |  |  | ↓3 | [[82](#_ENREF_82)] |
| R169P/G |  | Huh7 |  |  |  | ↓ | L3 | [[78](#_ENREF_78)] |
| Y100S + S143L | OBI | Huh7 | L |  |  |  |  | [[77](#_ENREF_77)] |
| M103I + G145A | OBI | Huh7/HepG2 | ↓ |  | ↓ | ↓ |  | [[86](#_ENREF_86)] |
| M103I + R122K + G145A | OBI | Huh7/HepG2 | ↓ |  | ↓ | ↓ |  | [[86](#_ENREF_86)] |
| T115I + T116N | CHB | HepG2 | ↓or L |  |  |  |  | [[87](#_ENREF_87)] |
| T116N + S143L | OBI | Huh7 | ↓ |  |  |  |  | [[77](#_ENREF_77)] |
| R122P + Q101R | OBI | Huh7 | ↓ |  |  |  |  | [[77](#_ENREF_77)] |
| R122P + S167L | OBI | Huh7 | ↓ |  |  |  |  | [[77](#_ENREF_77)] |
| R122K + G145A | OBI | Huh7/HepG2 | ↓ |  | ↓ | ↓ |  | [[86](#_ENREF_86)] |
| P142A + D144V | KT | Huh7 | ↓ |  |  |  |  | [[85](#_ENREF_85)] |
| A159G + K160N |  | Huh7/Hela | ↓ | ↑5 |  |  | ↓3 | [[82](#_ENREF_82)] |

1stop codon mutation; 2Viral replication; 3Viral secretion; 4correct that I110M, G119E, G145R, N146Q/S, R169H mutations lead to the decrease of viral secretion; 5cell-mediated immunity; ↑: increase; ↓: decrease. Intra-HBsAg: intracellular HBsAg; Extra-HBsAg: extracellular HBsAg; L: Dramatic decrease; CHB: Chronic hepatitis B; OBI: Occult HBV infection; LC: Liver cirrhosis; KT: Kidney transplant; LT: Liver transplant; HBsAg: hepatitis B virus surface antigen.